Pioglitazone is a thiazolidinedione antidiabetic agent that increases insulin sensitivity and decreases hepatic gluconeogenesis. Administered once daily without regard to meals, it is well absorbed, and is metabolised by the hepatic cytochrome P450 enzyme system. The half-life of the drug is approxi...
No comments yet
Be the first to share your thoughts!